Neumora Therapeutics, Inc. (NMRA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neumora Therapeutics, Inc. on February 11, 2026. The filing serves as a Regulation FD disclosure to make a corporate presentation available to investors and analysts ahead of the Guggenheim Emerging Outlook: Biotech Summit 2026.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate presentation rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the text of this 8-K filing. The primary event is the distribution of the corporate presentation referenced in Exhibit 99.1.
Guidance, Outlook, and Risks
The filing explicitly states that the information contained in the corporate presentation (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, the presentation is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933. The text notes that this information shall not be incorporated by reference into any other SEC filings made by the Company.
Key Facts for Investor Verification
- Verify the content of the corporate presentation in Exhibit 99.1 for specific business updates, as the 8-K text only references its existence.
- Note that the presentation is not legally "filed" and carries different liability standards than standard SEC filings.
- Confirm the date of the Guggenheim Emerging Outlook: Biotech Summit 2026 to understand the context of the disclosure.
- Review the Company's most recent 10-K or 10-Q for actual financial metrics, as this 8-K contains none.